CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
Fentanyl Transdermal System +1 moredrug
Likely dose
Fentanyl Transdermal System 50 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04204967
NCT04204967Phase 2Completed

Impact of Totally Transdermal Sedation in the Weaning From Remifentanil Infusion Among Critically Ill Patients Undergoing Mechanical Ventilation: a Pilot Randomized-controlled Study (The TOES Trial)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS·interventional·Posted Dec 19, 2019·Updated May 17, 2024

In Brief

A Phase 2 clinical trial evaluating Fentanyl Transdermal System and Remifentanil for Respiratory Insufficiency and 2 related conditions. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The choice of the sedation protocol has a massive impact on the duration of mechanical ventilation and the timing of extubation. Many sedation protocols are described in the literature. The investigators aim to assess if a transdermal fentanyl-based sedation protocol can have an impact on the global Work of Breathing (WOB)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesItaly
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedDec 19, 2019
Enrollment StartFeb 15, 2021
Primary CompletionApr 6, 2024
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 6.5 years ago

Interventions

Fentanyl Transdermal Systemdrug

in the experimental arm transdermal fentanyl will be administered with a starting dose of 50 mcg/hr simultaneously with the preexistent remifentanil continue infusion. Remifentanil infusion rate will be increased or decreased based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit. After randomization, the transdermal fentanyl dose can be modified every 24 hours according to the study protocol to achieve the desired effect in terms of PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected

Remifentanildrug

In the active comparator arm remifentanil infusion is administered alone, the infusion rate will be increased or decreased according to the study protocol based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit. In the experimental arm remifentanil is use together with transdermal fentanyl